stocks logo

ATHE

Alterity Therapeutics Ltd
$
6.550
+0.87(15.317%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.000
Open
5.870
VWAP
6.48
Vol
258.16K
Mkt Cap
60.31B
Low
5.850
Amount
1.67M
EV/EBITDA(TTM)
--
Total Shares
8.73M
EV
142.89M
EV/OCF(TTM)
--
P/S(TTM)
303.64
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Show More
1 Analyst Rating
up Image
83.21% Upside
Wall Street analysts forecast ATHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
83.21% Upside
Current: 6.550
sliders
Low
12.00
Averages
12.00
High
12.00
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$8 → $12
2025-01-30
Reason
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$8
2024-12-12
Reason
Maxim initiated coverage of Alterity Therapeutics with a Buy rating and $8 price target.

Valuation Metrics

The current forward P/E ratio for Alterity Therapeutics Ltd (ATHE.O) is -9.08, compared to its 5-year average forward P/E of -18.76. For a more detailed relative valuation and DCF analysis to assess Alterity Therapeutics Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.76
Current PE
-9.08
Overvalued PE
82.75
Undervalued PE
-120.27

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.47
Current EV/EBITDA
-7.26
Overvalued EV/EBITDA
0.74
Undervalued EV/EBITDA
-1.68

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
9.77
Current PS
38.95
Overvalued PS
16.75
Undervalued PS
2.78

Financials

Annual
Quarterly

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

ATHE News & Events

Events Timeline

2025-07-24 (ET)
2025-07-24
07:30:15
Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study
select
2025-05-05 (ET)
2025-05-05
07:36:10
Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434
select
2025-04-30 (ET)
2025-04-30
07:40:44
Alterity Therapeutics reports cash balance of A$17.96M as of March 31
select
Sign Up For More Events

News

3.5
07-24Newsfilter
PinnedAlterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
9.5
07-11Benzinga
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
9.0
05-07Newsfilter
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Sign Up For More News

FAQ

arrow icon

What is Alterity Therapeutics Ltd (ATHE) stock price today?

The current price of ATHE is 6.55 USD — it has increased 15.32 % in the last trading day.

arrow icon

What is Alterity Therapeutics Ltd (ATHE)'s business?

arrow icon

What is the price predicton of ATHE Stock?

arrow icon

What is Alterity Therapeutics Ltd (ATHE)'s revenue for the last quarter?

arrow icon

What is Alterity Therapeutics Ltd (ATHE)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Alterity Therapeutics Ltd (ATHE)'s fundamentals?

arrow icon

How many employees does Alterity Therapeutics Ltd (ATHE). have?

arrow icon

What is Alterity Therapeutics Ltd (ATHE) market cap?